Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,176-1,200 of 2,022
CompletedNCT06319170

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

This study exists to better understand the safety of this type of care and how manageable it feels in practice. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Condition
Schizophrenia
TerminatedNCT03900754

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

This study exists to understand what helps a digital app or remote support tool work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
CompletedNCT07305779

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT06315283

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

This study exists to see whether the medication TV-44749 can play a useful role in care. Researchers are trying to understand how people respond to the medication TV-44749 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Croatia, Spain, United Kingdom, United States
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Condition
Schizophrenia
CompletedNCT07326618

Cinematic Virtual Reality Intervention for Improving Psychosocial Functioning in Individuals With Schizophrenia

This study exists to understand what helps a digital app or remote support tool work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Turkey
Sponsor
Dokuz Eylul University
Condition
Schizophrenia
CompletedNCT05660018

TMS Related Biomarker Assessments

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT06993831

ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia

This study exists to understand how a therapy or guided support program holds up over time after the earliest research stage. Researchers are trying to understand whether a therapy or guided support program can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
Denmark
Sponsor
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Condition
Schizophrenia
CompletedNCT01626872

Long-Term Study of MP-214 in Patients With Schizophrenia

This study exists to understand how the medication MP-214 holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 20 Years to 65 Years
Countries
Japan, South Korea, Taiwan
Sponsor
Tanabe Pharma Corporation
Condition
Schizophrenia
CompletedNCT01625000

Safety and Efficacy of MP-214 in Patients With Schizophrenia

This study exists to understand whether the medication MP-214 is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 20 Years to 64 Years
Countries
Japan, South Korea, Taiwan
Sponsor
Tanabe Pharma Corporation
Condition
Schizophrenia
CompletedNCT01626859

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

This study exists to understand whether the medication MP-214 is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 20 Years to 64 Years
Countries
Japan
Sponsor
Tanabe Pharma Corporation
Condition
Schizophrenia
CompletedNCT04681807

Social Cognition in Youth Who Have a First Degree Relative With Schizophrenia

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 15 Years to 35 Years
Countries
Canada
Sponsor
The Royal Ottawa Mental Health Centre
Condition
Schizophrenia
CompletedNCT04115319

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Romania, Russian Federation, Ukraine, United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
TerminatedNCT04986072

Sodium Nitroprusside in Early Course Schizophrenia

This study exists to see whether blood tests and biological markers can make care clearer and more responsive. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United States
Sponsor
Beth Israel Deaconess Medical Center
Condition
Schizophrenia
CompletedNCT07310615

Mindfulness Psychoeducation for Schizophrenia

This study exists to see whether psychoeducation, a guided learning and support program, can make care clearer and more responsive. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Turkey
Sponsor
Ömer USLU
Condition
Schizophrenia
CompletedNCT01373866

Multimodal MRI-guided rTMS to Treat Refractory Hallucinations

This study exists to understand what helps brain scans or other body measurements work in everyday practice, not just under ideal conditions. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 13 Years to 60 Years
Countries
France
Sponsor
University Hospital, Lille
Condition
Schizophrenia
CompletedNCT02150174

Testing Effect and Schizophrenia

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
CompletedNCT04517279

Peer Approaches to Substances in Early Psychosis Programs: A Pilot Study of a Peer-Led Intervention

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can work better when mental health difficulties overlap with substance use.

SchizophreniaOtherFrom 15 Years to 32 Years
Countries
United States
Sponsor
University of Texas at Austin
Condition
Schizophrenia
CompletedNCT02570594

Autobiographical Memory Organization in Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
CompletedNCT02744989

STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
France, Monaco
Sponsor
Hospices Civils de Lyon
Condition
Schizophrenia
CompletedNCT06608498

DMHI for At-Risk College Students

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 18 Years to 30 Years
Countries
United States
Sponsor
University of Washington
Condition
Schizophrenia
CompletedNCT06389266

Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia

This study exists to compare options and see whether smoking support or smoking-related treatment offers something meaningfully different. Researchers are trying to understand whether smoking support or smoking-related treatment can better support energy, concentration, and everyday functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanderbilt University Medical Center
Condition
Schizophrenia
CompletedNCT05919823

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
China
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia